Precise Capture and Dynamic Release of Circulating Liver Cancer Cells with Dual-Histidine-Based Cell Imprinted Hydrogels

Precise Capture and Dynamic Release of Circulating Liver Cancer Cells with Dual-Histidine-Based Cell Imprinted Hydrogels

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 27 vom: 02. Juli, Seite e2402379
1. Verfasser: Sun, Wenjing (VerfasserIn)
Weitere Verfasser: You, Xin, Zhao, Xinjia, Zhang, Xiaoyu, Yang, Chunhui, Zhang, Fusheng, Yu, Jiaqi, Yang, Kaiguang, Wang, Jixia, Xu, Fangfang, Chang, Yongxin, Qu, Boxin, Zhao, Xinmiao, He, Yuxuan, Wang, Qi, Chen, Jinghua, Qing, Guangyan
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article cell imprinting circulating tumor cells early diagnosis glycans hydrogels interfaces recognition Hydrogels Histidine 4QD397987E Polymers
Beschreibung
Zusammenfassung:© 2024 Wiley‐VCH GmbH.
Circulating tumor cells (CTCs) detection presents significant advantages in diagnosing liver cancer due to its noninvasiveness, real-time monitoring, and dynamic tracking. However, the clinical application of CTCs-based diagnosis is largely limited by the challenges of capturing low-abundance CTCs within a complex blood environment while ensuring them alive. Here, an ultrastrong ligand, l-histidine-l-histidine (HH), specifically targeting sialylated glycans on the surface of CTCs, is designed. Furthermore, HH is integrated into a cell-imprinted polymer, constructing a hydrogel with precise CTCs imprinting, high elasticity, satisfactory blood compatibility, and robust anti-interference capacities. These features endow the hydrogel with excellent capture efficiency (>95%) for CTCs in peripheral blood, as well as the ability to release CTCs controllably and alive. Clinical tests substantiate the accurate differentiation between liver cancer, cirrhosis, and healthy groups using this method. The remarkable diagnostic accuracy (94%), lossless release of CTCs, material reversibility, and cost-effectiveness ($6.68 per sample) make the HH-based hydrogel a potentially revolutionary technology for liver cancer diagnosis and single-cell analysis
Beschreibung:Date Completed 04.07.2024
Date Revised 04.07.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-4095
DOI:10.1002/adma.202402379